Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 Million in 2023, exhibiting a CAGR of 5.7% during the forecast period (2023-2030).
Figure 1. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (%), By Type, 2023
Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market– Drivers
Rising cancer prevalence will increase the number of chemotherapies is expected to drive the global cancer chemotherapy associated nausea and vomiting therapeutics market growth over the forecast period. For instance, according to the data provided by the World Health Organization, in February 2022, the most common types of cancer were breast cancer accounting for 2.26 million cases and lung cancer accounting for 2.21 million cases in the year 2020, globally. Moreover, according to the data provided by the World Health Organization in February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.
Figure 2. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (US$ Million), By Region, 2023
Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients